Pieces are in Place
We’re about five weeks into this market correction, and it’s been a pretty nasty one when looking at the major indexes—from high to low, the S&P 500 has fallen as much as 7.6% and the Nasdaq by 10.8%, with small- mid-cap...
Read More
In this topsy-turvy market, it helps to know how the big hedge funds and institutions are spending their money. This Options Barometer gives you the answer.
Read More
Identifying the best ETFs of 2017 is a good predictor of what sectors have plenty of momentum heading into 2018. Here are five that stood out.
Read More
After two months of churn, biotech stocks are suddenly red-hot thanks to a blockbuster Gilead-Kite Pharma deal that's propping up the entire sector.
Read More
The best pharma stocks can be hard to find in a pharmaceutical industry rife with high-stakes conflicts over regulatory approvals, pricing and marketing.
Read More
All things considered, the past week has been tame. The S&P 600 Small Cap Index retreated 1.4% to get back to its 50-day moving average, while the S&P 500 Index traded sideways.
Read More
Once a high riser, the IHE biotech ETF has been stuck in the mud for two years. But that doesn't mean you should tune out the biopharma industry as a whole.
Read More
Stocks are rallying after Trump's win, but small cap stocks are outpacing them all. Here are three small cap sectors that are faring particularly well.
Read More
Donald Trump's surprise victory has some ETFs soaring, and some crashing. Here are the funds you should buy, and which you should avoid, in the weeks ahead.
Read More
We’re going to reel in a few profits during this post-election stock market surge in the event the honeymoon is short-lived. Along those lines, today I recommend you sell your remaining stake in Mitek (MITK), as well as sell half your position in Vascular...
Read More
We may look to exit a few positions on strength over the coming weeks/months, but those moves will depend on share price momentum and/or earnings results. More companies have announced their earnings release dates, and three companies report next week. We have ratings...
Read More
Insider trading is an unfortunate reality of the stock market, but options trading allows you to legally profit from some of these nefarious moves.
Read More
There are no ratings changes today. My stance is cautiously optimistic, and favors resisting the temptation to chase stocks. Action is going to pick up next week as we have Blackbaud (BLKB), LogMeIn (LOGM) and Mitek (MITK) reporting. I’m expecting good things from all.
Read More
Just received this information from yesterday’s Thomson Reuters Lipper report regarding fund inflows/outflows. It’s interesting to see which funds are being sold and which are attracting new money:
“For the second week in a row, equity ETFs witnessed net outflows; however, this past week handed...
Read More
In this week’s Stock Market Video, Mike Cintolo discusses his "lean bullish" stance toward the market as the evidence continues to improve, especially when it comes to growth stocks—in fact, he's most impressed with the number of "liquid leaders" that have launched of usually...
Read More
Biotech stocks have been red-hot this year, and a major reason for it is the glut of promising treatments being developed for diseases that have long been woefully undertreated.
Read More
